Publication | Closed Access

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

Phase 1/2MedicineImmunologyPathologyCheckmate 370Immune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyLung CancerMolecular OncologyNivolumab Plus Crizotinib